Literature DB >> 8223846

New strategies in drug development and clinical evaluation: the population approach. Commentary on an action for co-operative research.

L P Balant1, M Rowland, L Aarons, F Mentré, P L Morselli, J L Steimer, S Vozeh.   

Abstract

Mesh：

Year:  1993        PMID： 8223846     DOI： 10.1007/bf00315486

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  5 in total

1.  Population pharmacokinetics and pharmacodynamics: potential use for gathering dose-concentration-response.

Authors:  M Jerling
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

Review 2.  The use of population pharmacokinetics in drug development.

Authors:  S Vozeh; J L Steimer; M Rowland; P Morselli; F Mentre; L P Balant; L Aarons
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

3.  Do we need full compliance data for population pharmacokinetic analysis?

Authors:  P Girard; L B Sheiner; H Kastrissios; T F Blaschke
Journal:  J Pharmacokinet Biopharm       Date:  1996-06

4.  Pharmacokinetic analysis of sparse in vivo NMR spectroscopy data using relative parameters and the population approach.

Authors:  R E Port; H P Schlemmer; P Bachert
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

5.  Are we doing too many animal biodisposition investigations before phase I studies in man? A re-evaluation of the timing and extent of ADME studies.

Authors:  D B Campbell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Jul-Sep       Impact factor: 2.441
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.